published on 03.11.2017
At the Liver Meeting of the AASLD (American Association for the Study of Liver Diseases) end of October 2017 in Washington D.C. data from a comparative clinical study on extracorporeal albumin dialysis (ECAD) has been presented this year. Twelve liver patients have been treated both with the previous standard setup and with the new OPAL setup. The OPAL setup includes the Hepalbin-Cluster12. It was shown that using the Hepalbin-Cluster12 more bilirubin and more bile acids could be removed compared to the standard setup. In addition, the involvement of the Hepalbin-Cluster12 significantly improved the albumin-binding function in the patient cycle, whereas in the standard setup this was not the case.
The presented poster can be downloaded here.
The poster presentation was honored as the "Poster of Distinction" in the AASLD review process and thus represents a scientific contribution of the top 10% in the ranking of all submissions.
The abstract (No. 1244) for presentation was published in the Journal Hepatology of Wiley-Verlag. (DOI: 10.1002 / hep.29501)
Albutec GmbH • Schillingallee 68 • 18057 Rostock • Germany Phone: +49-381-12165871 • Fax: +49-381-12165877